٠٠:٠٣:٥٧Head of the Jordan Centre for Disease Control (JCDC) Dr Adel Al-Balbisi said that the country would 'continue to monitor' for mpox, after the first case of the disease was detected this year, speaking during an interview on Tuesday.
"We’ll continue to monitor the disease. We have notified all health teams and hospitals that whoever suffers from skin lesions must be tested for mpox," he said. "We have procedures in force at the crossing borders for those arriving from African countries to ensure they are not infected.”
Jordan's Health Ministry first announced on Monday that the country registered a case, although the exact variant was not reported.
"In 2022, a mpox case was also detected," Dr Al-Balbisi continued. "This time, the patient is a non-Jordanian male resident, i.e. he was infected while living here. He is now in quarantine in a hospital to prevent the spread of infection. He is in a very good condition but must be isolated for 2-4 weeks, which is the period needed for recovery.”
The Ministry of Health confirmed that the patient, aged 33, was in isolation at Al-Basheer Hospitals in Amman and was in a 'stable medical condition'.
In August, the WHO announced a public health emergency due to the spread of the Clade Ib type of the disease, currently in Africa. Over 16,000 cases of mpox - and more than 500 deaths- reported in the DRC alone.
The new variant can kill up to 10 percent of those infected, according to reports, Sweden and Thailand have recorded cases of Clade 1. The less dangerous Clade II, which caused the global outbreak in 2022, has a fatality rate of less than one percent but can still cause serious public health concerns.
According to the WHO, mpox spreads through close physical interactions and contaminated items such as bedding, clothing, or needles. The virus causes flu-like symptoms and skin lesions and can be transmitted both among humans and from animals to humans. While vaccines do exist, they are typically only available to those at risk or in close contact with confirmed cases.
‘We’ll continue to monitor the disease' - Head of Jordan Centre for Disease Control as country records first mpox case in 2024
Head of the Jordan Centre for Disease Control (JCDC) Dr Adel Al-Balbisi said that the country would 'continue to monitor' for mpox, after the first case of the disease was detected this year, speaking during an interview on Tuesday.
"We’ll continue to monitor the disease. We have notified all health teams and hospitals that whoever suffers from skin lesions must be tested for mpox," he said. "We have procedures in force at the crossing borders for those arriving from African countries to ensure they are not infected.”
Jordan's Health Ministry first announced on Monday that the country registered a case, although the exact variant was not reported.
"In 2022, a mpox case was also detected," Dr Al-Balbisi continued. "This time, the patient is a non-Jordanian male resident, i.e. he was infected while living here. He is now in quarantine in a hospital to prevent the spread of infection. He is in a very good condition but must be isolated for 2-4 weeks, which is the period needed for recovery.”
The Ministry of Health confirmed that the patient, aged 33, was in isolation at Al-Basheer Hospitals in Amman and was in a 'stable medical condition'.
In August, the WHO announced a public health emergency due to the spread of the Clade Ib type of the disease, currently in Africa. Over 16,000 cases of mpox - and more than 500 deaths- reported in the DRC alone.
The new variant can kill up to 10 percent of those infected, according to reports, Sweden and Thailand have recorded cases of Clade 1. The less dangerous Clade II, which caused the global outbreak in 2022, has a fatality rate of less than one percent but can still cause serious public health concerns.
According to the WHO, mpox spreads through close physical interactions and contaminated items such as bedding, clothing, or needles. The virus causes flu-like symptoms and skin lesions and can be transmitted both among humans and from animals to humans. While vaccines do exist, they are typically only available to those at risk or in close contact with confirmed cases.
Head of the Jordan Centre for Disease Control (JCDC) Dr Adel Al-Balbisi said that the country would 'continue to monitor' for mpox, after the first case of the disease was detected this year, speaking during an interview on Tuesday.
"We’ll continue to monitor the disease. We have notified all health teams and hospitals that whoever suffers from skin lesions must be tested for mpox," he said. "We have procedures in force at the crossing borders for those arriving from African countries to ensure they are not infected.”
Jordan's Health Ministry first announced on Monday that the country registered a case, although the exact variant was not reported.
"In 2022, a mpox case was also detected," Dr Al-Balbisi continued. "This time, the patient is a non-Jordanian male resident, i.e. he was infected while living here. He is now in quarantine in a hospital to prevent the spread of infection. He is in a very good condition but must be isolated for 2-4 weeks, which is the period needed for recovery.”
The Ministry of Health confirmed that the patient, aged 33, was in isolation at Al-Basheer Hospitals in Amman and was in a 'stable medical condition'.
In August, the WHO announced a public health emergency due to the spread of the Clade Ib type of the disease, currently in Africa. Over 16,000 cases of mpox - and more than 500 deaths- reported in the DRC alone.
The new variant can kill up to 10 percent of those infected, according to reports, Sweden and Thailand have recorded cases of Clade 1. The less dangerous Clade II, which caused the global outbreak in 2022, has a fatality rate of less than one percent but can still cause serious public health concerns.
According to the WHO, mpox spreads through close physical interactions and contaminated items such as bedding, clothing, or needles. The virus causes flu-like symptoms and skin lesions and can be transmitted both among humans and from animals to humans. While vaccines do exist, they are typically only available to those at risk or in close contact with confirmed cases.